Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen

Preferred Label : Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen;

NCIt synonyms : Bortezomib/Daratumumab/Dexamethasone/Lenalidomide; Daratumumab-RVD; RVD Regimen Plus Daratumumab; Darzalex-RVD; D-RVD Regimen; Bortezomib-Lenalidomide-Dexamethasone Plus Daratumumab; Bortezomib/Lenalidomide/Dexamethasone Plus Daratumumab; Bortezomib/Lenalidomide/Dexamethasone Plus Daratumumab Regimen; Bortezomib-Daratumumab-Dexamethasone-Lenalidomide; Velcade/Revlimid/Dexamethasone-Darzalex; Bortezomib-Daratumumab-Dexamethasone-Lenalidomide Regimen; RVD Plus Darzalex; Dara-RVd;

NCIt definition : A chemoimmunotherapy regimen consisting of bortezomib, daratumumab, dexamethasone and lenalidomide that can be used for the treatment of plasma cell (multiple) myeloma.;

NCI Metathesaurus CUI : CL1664476;

Codes from synonyms : 6472;

Details

Origin ID

C181580;

UMLS CUI

C5557164;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Bortezomib [NCIt concept]
- Daratumumab [NCIt concept]
- Dexamethasone [NCIt concept]
- Lenalidomide [NCIt concept]
concept_is_in_subset
- HemOnc Regimen Terminology [NCIt concept]
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients